On December 21, 2017 Hookipa Biotech AG ("Hookipa"), a clinical stage biotech company pioneering an innovative class of immune activation therapies for oncology and infectious diseases, reported that CEO Joern Aldag will be presenting at the 36th Annual J.P. Morgan Healthcare Conference that is being held in San Francisco, CA from January 8-11, 2018 (Press release, Hookipa Biotech, DEC 21, 2017, View Source [SID1234522766]). The Company’s presentation is scheduled for Wednesday, January 10 at 04:30 PM Pacific Standard Time.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Mr. Aldag will provide an overview of the Company´s strategy as well as an update on its development programs, including its progress on two proof-of concept clinical trials and its plan to expand its technology platform into other disease areas.